Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years.
Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years.